Posted by Michael Wonder on 21 Dec 2023
Calliditas Therapeutics announces full FDA approval of Tarpeyo, the only FDA approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
20 December 2023 - Calliditas Therapeutics today announced that the US FDA has approved Tarpeyo (budesonide) delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy at risk for disease progression.
Tarpeyo was first approved in December 2021 under accelerated approval, based on the surrogate marker of proteinuria.
